| Size | Price | |
|---|---|---|
| 500mg | ||
| Other Sizes |
| Targets |
Nortropine targets the cholinergic system through its anticholinergic properties. As a tropane alkaloid, it is structurally related to tropine and other tropane derivatives that interact with muscarinic acetylcholine receptors. The compound’s mechanism involves blocking the action of acetylcholine at muscarinic receptors, leading to anticholinergic effects. Nortropine is an intermediate in tropine metabolism, and its breakdown leads to succinate. Its interactions with the cholinergic system make it of interest in medicinal chemistry.
|
|---|---|
| ln Vitro |
Nortropine exhibits in vitro activity as a tropane alkaloid with potential pharmacological effects. It has been investigated for its anticholinergic properties. The compound is used as a pharmaceutical standard and intermediate in organic synthesis. Its activity is assessed in receptor binding assays to measure its affinity for muscarinic acetylcholine receptors. These in vitro activities confirm its potential as a research tool for studying cholinergic signaling and tropane alkaloid pharmacology.
|
| ln Vivo |
In vivo activity of Nortropine has been studied in the context of its anticholinergic properties. As a tropane alkaloid, it may produce effects similar to other anticholinergic agents, including inhibition of salivation, bronchodilation, and effects on the central nervous system. However, detailed in vivo data are limited, as the compound is primarily used as an intermediate and research standard. Further studies would be needed to fully characterize its in vivo effects and therapeutic potential.
|
| Enzyme Assay |
In vitro receptor binding assays for Nortropine involve measuring its affinity for muscarinic acetylcholine receptors. These assays typically use membrane preparations from tissues or cells expressing muscarinic receptors and a radiolabeled antagonist. The compound is incubated with the receptor and the radioligand, and the displacement is measured to calculate the binding affinity. These assays confirm the compound’s interaction with the cholinergic system.
|
| Cell Assay |
In vitro cellular assays for Nortropine are conducted in cells expressing muscarinic acetylcholine receptors. Cells are treated with the compound at various concentrations, and receptor-mediated signaling is measured using calcium flux or other signaling readouts. Cell viability is assessed to ensure that observed effects are not due to cytotoxicity. These assays characterize the compound’s activity as a muscarinic receptor ligand.
|
| Animal Protocol |
In vivo animal experiments with Nortropine are not extensively documented, as the compound is primarily used as an intermediate and research standard. However, its anticholinergic properties could be studied in animal models of cholinergic dysfunction. The compound would be administered via injection, and endpoints would include behavioral and physiological measures of cholinergic activity. These studies would help define its in vivo effects.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Nortropine are limited. The compound has a molecular weight of 127.18 and is a small, polar molecule. It is soluble in organic solvents. Its bioavailability and half-life have not been extensively characterized. The compound is primarily used as an intermediate and research standard. Further PK studies would be needed if the compound were to be developed as a therapeutic agent.
|
| Toxicity/Toxicokinetics |
Nortropine is considered to have low toxicity based on its use as a research compound. However, as a tropane alkaloid, it may have anticholinergic effects at high doses. The compound is intended for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling this compound. Further toxicity studies would be required to support any potential clinical development.
|
| References |
|
| Additional Infomation |
Nortropine is a tropane alkaloid and an intermediate in tropine metabolism. It is also known as Nortropenol, 1-alpha-h,5-alpha-h-nortropan-3-alpha-ol, and 8-azabicyclo[3.2.1]octan-3-ol. The compound is isolated from Convolvulus subhirsutus alkaloids and is used as a pharmaceutical standard, metabolite, impurity, and intermediate. Nortropine has been investigated for its anticholinergic properties and may have applications in medicinal chemistry. It is available in high purity (>99%) for research applications.
|
| Molecular Formula |
C7H13NO
|
|---|---|
| Molecular Weight |
127.1842
|
| Exact Mass |
122.073
|
| CAS # |
538-09-0
|
| PubChem CID |
73480
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
218.2±8.0 °C at 760 mmHg
|
| Melting Point |
108-110ºC
|
| Flash Point |
102.2±0.0 °C
|
| Vapour Pressure |
0.1±0.5 mmHg at 25°C
|
| Index of Refraction |
1.536
|
| LogP |
1.36
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
104
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1C[C@H]2CC(C[C@@H]1N2)O
|
| InChi Key |
YYMCYJLIYNNOMK-MEKDEQNOSA-N
|
| InChi Code |
InChI=1S/C7H13NO/c9-7-3-5-1-2-6(4-7)8-5/h5-9H,1-4H2/t5-,6+,7?
|
| Chemical Name |
(1R,5S)-8-azabicyclo[3.2.1]octan-3-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~33.33 mg/mL (~262.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (19.66 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (19.66 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.8629 mL | 39.3144 mL | 78.6287 mL | |
| 5 mM | 1.5726 mL | 7.8629 mL | 15.7257 mL | |
| 10 mM | 0.7863 mL | 3.9314 mL | 7.8629 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
